Comparing Smoking Treatment Programs for Lighter Smokers - 1
NCT ID: NCT00086411
Last Updated: 2019-08-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
260 participants
INTERVENTIONAL
2003-09-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
NCT00364156
Treatment to Quit Smoking
NCT00018161
Non-Nicotine Agents for Smoking Cessation
NCT00108537
Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals
NCT00308763
Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects
NCT06254001
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: Bup+MM
bupropion and MM counseling with placebo patch
bupropion
150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
Medication Management
Brief manual based therapy; four 15 minute session over 10 weeks.
placebo patch
placebo patch containing no nicotine
2 Bup+Mayo
bupropion and Mayo counseling with placebo patch.
bupropion
150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
Mayo Counseling
Manual based therapy; Weekly 30 minute sessions for 10 weeks
placebo patch
placebo patch containing no nicotine
3 Patch+MM
patch and MM counseling with placebo pills
nicotine transdermal system
starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
Medication Management
Brief manual based therapy; four 15 minute session over 10 weeks.
placebo bupropion
placebo pills
4 Patch+Mayo
patch and Mayo counseling with placebo pills
nicotine transdermal system
starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
Mayo Counseling
Manual based therapy; Weekly 30 minute sessions for 10 weeks
placebo bupropion
placebo pills
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nicotine transdermal system
starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
bupropion
150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
Medication Management
Brief manual based therapy; four 15 minute session over 10 weeks.
Mayo Counseling
Manual based therapy; Weekly 30 minute sessions for 10 weeks
placebo patch
placebo patch containing no nicotine
placebo bupropion
placebo pills
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter W Gariti, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gariti P, Levin S, Whittingham T, Barou D, Kampman KM, Lynch K, Halbert CH, Alterman A. Why do those who request smoking treatment fail to attend the first appointment? J Subst Abuse Treat. 2008 Jul;35(1):62-7. doi: 10.1016/j.jsat.2007.08.009. Epub 2007 Oct 10.
Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat. 2009 Oct;37(3):247-55. doi: 10.1016/j.jsat.2009.01.006. Epub 2009 Mar 31.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-15365-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.